Quest Diagnostics Incorporated (LON:0KSX)
180.60
-0.52 (-0.29%)
At close: Sep 16, 2025
Quest Diagnostics Employees
As of December 31, 2024, Quest Diagnostics had 56,000 total employees, including 45,000 full-time and 11,000 part-time employees. The number of employees increased by 8,000 or 16.67% compared to the previous year.
Employees
56,000
Change (1Y)
8,000
Growth (1Y)
16.67%
Revenue / Employee
152.08K GBP
Profits / Employee
13.66K GBP
Market Cap
14.76B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56,000 | 8,000 | 16.67% |
Dec 31, 2023 | 48,000 | -1,000 | -2.04% |
Dec 31, 2022 | 49,000 | 0 | - |
Dec 31, 2021 | 49,000 | 0 | - |
Dec 31, 2020 | 49,000 | 2,000 | 4.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Quest Diagnostics News
- 15 days ago - Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index - PRNewsWire
- 22 days ago - Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan - PRNewsWire
- 23 days ago - FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics - PRNewsWire
- 4 weeks ago - Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference - PRNewsWire
- 4 weeks ago - Quest Diagnostics declares $0.80 dividend - Seeking Alpha
- 5 weeks ago - Quest Diagnostics Declares Quarterly Cash Dividend - PRNewsWire
- 5 weeks ago - What Does the Market Think About Quest Diagnostics? - Benzinga
- 5 weeks ago - Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types - PRNewsWire